STOCK TITAN

DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
DiaMedica Therapeutics CEO to participate in Lake Street Capital Market's conference
Positive
  • None.
Negative
  • None.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023. Management will conduct one-on-one meetings with investors during the conference.

To receive additional information or to schedule a one-on-one meeting, please contact your Lake Street Capital Markets representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

DMAC Rankings

DMAC Latest News

DMAC Stock Data

182.96M
42.75M
26.23%
30.55%
0.43%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MINNEAPOLIS